Waverley Pharma Inc. (FRA:5GZ)

Market Cap	502.78K -0.8%
Revenue (ttm)	773.81K +43.7%
Net Income	-390.58K
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0060
Previous Close	0.0060
Day's Range	0.0060 - 0.0060
52-Week Range	0.0040 - 0.0120
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 1, 2026

About Waverley Pharma

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5GZ

Financial Performance

In 2025, Waverley Pharma's revenue was 1.35 million, an increase of 183.90% compared to the previous year's 475,373. Losses were -499,214, -47.29% less than in 2024.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error